Radius Health, Inc. (RDUS): Price and Financial Metrics


Radius Health, Inc. (RDUS)

Today's Latest Price: $12.66 USD

0.67 (-5.03%)

Updated May 29 4:00pm

Add RDUS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

RDUS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for RDUS is -2.58 -- better than only 3.91% of US stocks.
  • RDUS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 2.56% of US stocks.
  • As for revenue growth, note that RDUS's revenue has grown 67.11% over the past 12 months; that beats the revenue growth of 92.09% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Radius Health Inc are KPTI, NWBO, ATNX, XERS, and URG.
  • RDUS's SEC filings can be seen here. And to visit Radius Health Inc's official web site, go to www.radiuspharm.com.
RDUS Daily Price Range
RDUS 52-Week Price Range

RDUS Stock Price Chart More Charts


RDUS Price/Volume Stats

Current price $12.66 52-week high $29.97
Prev. close $13.33 52-week low $10.32
Day low $12.02 Volume 564,258
Day high $13.25 Avg. volume 625,084
50-day MA $13.81 Dividend yield N/A
200-day MA $20.51 Market Cap 587.28M

Radius Health, Inc. (RDUS) Company Bio


Radius Health is a biopharmaceutical company focused on developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive metastatic breast cancer. The company was founded in 2003 and is based in Waltham, Massachusetts.


RDUS Latest News Stream


Event/TimeNews Detail
Loading, please wait...

RDUS Latest Social Stream


Loading social stream, please wait...

View Full RDUS Social Stream

Latest RDUS News From Around the Web

Below are the latest news stories about Radius Health Inc that investors may wish to consider to help them evaluate RDUS as an investment opportunity.

Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint

Radius Health, Inc. (“Radius” or the “Company”) (RDUS), today announced that its partner, Teijin Pharma Limited, has submitted a New Drug Application for abaloparatide-SC in Japan for the treatment of osteoporosis in patients who are at high risk for fractures. The application is based on the positive results of the Phase III clinical study of abaloparatide-SC in Japan which included osteoporosis patients at high risk for fracture. “We are pleased that our partner Teijin has achieved this significant milestone toward the potential introduction of abaloparatide as a new treatment option for osteoporosis patients,” stated Kelly Martin, CEO of Radius.

Yahoo | May 27, 2020

Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass

Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.

Yahoo | May 8, 2020

Radius Health (RDUS) Q1 2020 Earnings Call Transcript

Before we begin, I'd like to remind you with our Safe Harbor slide that we'll have some forward-looking statements and include non-GAAP financial measures in our presentation today. Any forward-looking statements represent our views as of today only.

Yahoo | May 8, 2020

Radius Health Announces First Quarter 2020 Operating Results

TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic..

Yahoo | May 7, 2020

Radius Health (RDUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Radius Health (RDUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | April 30, 2020

Read More 'RDUS' Stories Here

RDUS Price Returns

1-mo -20.73%
3-mo -39.89%
6-mo -43.48%
1-year -42.40%
3-year -63.30%
5-year -73.75%
YTD -37.20%
2019 22.26%
2018 -48.10%
2017 -16.46%
2016 -38.20%
2015 58.16%

Continue Researching RDUS

Want to see what other sources are saying about Radius Health Inc's financials and stock price? Try the links below:

Radius Health Inc (RDUS) Stock Price | Nasdaq
Radius Health Inc (RDUS) Stock Quote, History and News - Yahoo Finance
Radius Health Inc (RDUS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.0215 seconds.